Sanofi (SNY)
Sanofi Expenses: 8.833B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SNY Expenses Rankings
| Overall | 97th percentile | 118 of 4430 |
| Sector | 98th percentile | 9 of 471 in Healthcare |
| Industry | 75th percentile | 5 of 20 in Drug Manufacturers - Major |
SNY Expenses Range, Past 5 Years
| Minimum | 6.374B | Mar 2009 |
| Maximum | 10.61B | Jun 2011 |
| Average | 8.309B |
About Expenses
Any cost incurred by a business for revenue generating activities.
YCharts calculates this number as Total Revenues - Net Income.
Learn More
You may also be interested in these SNY related companies
SNY News
Sanofi's (SNY) Genzyme Reports Statistically Significant Top-Line Data from TOWER
Jun 01, 7:14AM Street Insider
Jun 01, 7:14AM Street Insider
Sanofi's (SNY) Genzyme, Isis Pharma (ISIS) Says FDA Accepts NDA for KYNAMRO
May 29, 9:23AM Street Insider
May 29, 9:23AM Street Insider
Sanofi (SNY), Regeneron (REGN) Report Additional Positive Data from Study 1003 in Patients w/ heFH
May 29, 6:52AM Street Insider
May 29, 6:52AM Street Insider
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
May 25, 2:01PM Street Insider
May 25, 2:01PM Street Insider
Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix
May 17, 1:42PM Street Insider
May 17, 1:42PM Street Insider
$SNY why all the call interest today? Todays most active Options Sanofi 99.6% calls wow... http://stks.co/3qwq
about 16 days ago by justfurkids
about 16 days ago by justfurkids
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 17 days ago by abubnic
about 17 days ago by abubnic
5 Top International Dividend Stocks http://stks.co/3kyJ $SNY $CRH $ABB $SID $CS
about 23 days ago by myplaniq
about 23 days ago by myplaniq
$SNY - Closed out at the Initial Stop of $35.62 - http://stks.co/3kS9
about 23 days ago by TraderFoxxx
about 23 days ago by TraderFoxxx
Sanofi's (SNY) Genzyme Gets EMA, FDA Approval for Second Suite at Irish Plant
May 03, 7:37AM Street Insider
May 03, 7:37AM Street Insider
Emerging market push and Genzyme acquisition paying dividends for $SNY 9.9% sales growth significantly outperforming rivals $GSK and $AZN
about 35 days ago by sld1986
about 35 days ago by sld1986
Call $SNY "Stk revalues due to change in biz mix, geo. mix, and lack of patent exposure past '12" http://stks.co/3QzB $PFE $MRK $GSK
about 42 days ago by SumZero
about 42 days ago by SumZero
Quick Pitch: Long on $AZN Target Price: $62 http://stks.co/3Jz7 $SNY $NVS "Best downside protection among Pharma large caps"
about 50 days ago by SumZero
about 50 days ago by SumZero
$AAPL 3D camera patent in works. Who will get the nod as supplier? Either/or/both? $OVTI $SNY >> http://stks.co/3CBy
about 60 days ago by IncrementalWealth
about 60 days ago by IncrementalWealth
Trade Signal-New $SNY -BTO @ 38.08 Limit w/35.62 Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/pygmwen
about 81 days ago by TraderFoxxx
about 81 days ago by TraderFoxxx
News related to $SNY, currently +0.1% since open: 'FDA links once-promising pain drugs to bone decay' http://stks.co/2jWz
about 85 days ago by TradeBot
about 85 days ago by TradeBot
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNY | 33.43 | -0.60 | -1.76% | 91.26B |
| SNX | 32.83 | -0.52 | -1.56% | 1.236B |
| SNV | 1.71 | -0.20 | -10.47% | 1.513B |
| SNTS | 6.675 | +0.01 | +0.23% | 407.86M |
| SNTA | 5.11 | +0.30 | +6.24% | 277.20M |
| SNT | 0.245 | +0.01 | +6.52% | 21.13M |
| SGU | 3.93 | -0.02 | -0.51% | 242.14M |
| SGRP | 1.24 | +0.00 | +0.00% | 24.92M |
| SGOL | 160.51 | +5.92 | +3.83% | |
| SGNT | 15.98 | +0.03 | +0.19% | 444.69M |